GABA
Synaptic anomalies in autistic people support imbalance hypothesis
Increased excitatory and decreased inhibitory synapses in the prefrontal cortex of autistic people suggest broader impacts on brain function and connectivity.
![Research image of excitatory synapses in the prefrontal cortex.](https://www.thetransmitter.org/wp-content/uploads/2024/06/Fig2BD3BD-1200-1024x692.webp)
Synaptic anomalies in autistic people support imbalance hypothesis
Increased excitatory and decreased inhibitory synapses in the prefrontal cortex of autistic people suggest broader impacts on brain function and connectivity.
Neurotransmitter switch-up helps fan extreme stress into full-blown fear
The flip occurs when certain neurons in the dorsal raphe start to express the chemical GABA instead of glutamate, a new study shows.
![Image of the dorsal raphe area of the brain.](https://www.thetransmitter.org/wp-content/uploads/2024/04/DorsalRaphe-1200-1024x692.webp)
Neurotransmitter switch-up helps fan extreme stress into full-blown fear
The flip occurs when certain neurons in the dorsal raphe start to express the chemical GABA instead of glutamate, a new study shows.
Looking at eye tracking’s potential for clinical trials
This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.
![A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.](https://www.thetransmitter.org/wp-content/uploads/2023/01/844-going-on-trial-autism-drugs-01.jpg)
Looking at eye tracking’s potential for clinical trials
This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.
Trials of arbaclofen for autism yield mixed results
Autistic children taking the drug showed improvements in some behaviors but not in their social skills.
![Photograph of white pills and blister pack on blue pastel colored background.](https://www.thetransmitter.org/wp-content/uploads/2023/05/844-arbaclofen-CR-autism-INSAR.jpg)
Trials of arbaclofen for autism yield mixed results
Autistic children taking the drug showed improvements in some behaviors but not in their social skills.
Cannabis compound rebalances signaling to quell seizures in mice
Cannabidiol (CBD) blocks the action of a molecule that drives an overexcitability feedback loop in a rodent model of epilepsy.
![Research image of cultured neurons.](https://www.thetransmitter.org/wp-content/uploads/2023/03/844-CBD-mechanism-final.png)
Cannabis compound rebalances signaling to quell seizures in mice
Cannabidiol (CBD) blocks the action of a molecule that drives an overexcitability feedback loop in a rodent model of epilepsy.
Single gene insufficient to account for dup15q, Angelman traits
UBE3A, a key gene associated with both autism-linked conditions, can explain most — but not all — of the syndromes’ atypical neuronal properties.
Single gene insufficient to account for dup15q, Angelman traits
UBE3A, a key gene associated with both autism-linked conditions, can explain most — but not all — of the syndromes’ atypical neuronal properties.
Null and Noteworthy: Busting biomarkers; going after GABA; reproducibility illusion
In this edition of Null and Noteworthy, scientists find little to be excited about in research on biomarkers for neurodevelopmental conditions.
![Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results.](https://www.thetransmitter.org/wp-content/uploads/2022/04/844_Null2_01.jpg)
Null and Noteworthy: Busting biomarkers; going after GABA; reproducibility illusion
In this edition of Null and Noteworthy, scientists find little to be excited about in research on biomarkers for neurodevelopmental conditions.
Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses
Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.
![A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.](https://www.thetransmitter.org/wp-content/uploads/2023/01/844-going-on-trial-autism-drugs-01.jpg)
Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses
Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.
Mouse studies cast astrocytes as stars of sensory perception
Data from two separate research teams suggest the cells are key to sensory hypersensitivity in fragile X syndrome.
![Single astrocyte on black background.](https://www.thetransmitter.org/wp-content/uploads/2022/11/Astrocytes-fragileX-autism-844.jpg)
Mouse studies cast astrocytes as stars of sensory perception
Data from two separate research teams suggest the cells are key to sensory hypersensitivity in fragile X syndrome.
Building a better drug
Iama Therapeutics is hoping a new class of molecule will prove successful against an old target in autism.
![Laura Cancedda in Iama's lab.](https://www.thetransmitter.org/wp-content/uploads/2022/10/Laura-Cancedda-IAMA-drug-austim-844.jpg)
Building a better drug
Iama Therapeutics is hoping a new class of molecule will prove successful against an old target in autism.
Explore more from The Transmitter
New connectomes fly beyond the brain
Researchers are mapping the neurons in Drosophila’s ventral nerve cord, where the central nervous system meets the rest of the body.
![Research image of neurons in the fly’s ventral nerve cord.](https://www.thetransmitter.org/wp-content/uploads/2024/07/lede-motormodules-1200-1024x692.webp)
New connectomes fly beyond the brain
Researchers are mapping the neurons in Drosophila’s ventral nerve cord, where the central nervous system meets the rest of the body.
Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.
![Illustration of researchers talking to laypeople amidst strands of DNA.](https://www.thetransmitter.org/wp-content/uploads/2024/07/1200_Charman-1024x687.webp)
Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.
Cerebellar circuit may convert expected pain relief into real thing
The newly identified circuit taps into the brain’s opioid system to provide a top-down form of pain relief.
![](https://www.thetransmitter.org/wp-content/uploads/2024/07/paincircuit-1200-1024x692.webp)
Cerebellar circuit may convert expected pain relief into real thing
The newly identified circuit taps into the brain’s opioid system to provide a top-down form of pain relief.